NYSE:PKI - PerkinElmer Stock Price, News & Analysis

$82.04
-0.65 (-0.79 %)
(As of 08/20/2019 04:00 PM ET)
Today's Range
$81.99
Now: $82.04
$82.61
50-Day Range
$80.15
MA: $90.45
$98.95
52-Week Range
$71.83
Now: $82.04
$103.00
Volume29,295 shs
Average Volume823,943 shs
Market Capitalization$9.11 billion
P/E Ratio22.77
Dividend Yield0.34%
Beta1.25
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorComputer and Technology
CUSIP71404610
Phone781-663-6900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.78 billion
Cash Flow$5.4259 per share
Book Value$23.24 per share

Profitability

Net Income$237.93 million

Miscellaneous

Employees12,500
Market Cap$9.11 billion
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable

Receive PKI News and Ratings via Email

Sign-up to receive the latest news and ratings for PKI and its competitors with MarketBeat's FREE daily newsletter.


PerkinElmer (NYSE:PKI) Frequently Asked Questions

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer declared a quarterly dividend on Thursday, July 25th. Stockholders of record on Friday, October 18th will be paid a dividend of $0.07 per share on Friday, November 8th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.34%. The ex-dividend date of this dividend is Thursday, October 17th. View PerkinElmer's Dividend History.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) released its quarterly earnings data on Monday, July, 29th. The medical research company reported $1.00 EPS for the quarter, missing the Zacks' consensus estimate of $1.01 by $0.01. The medical research company had revenue of $722.50 million for the quarter, compared to the consensus estimate of $729.10 million. PerkinElmer had a return on equity of 16.07% and a net margin of 9.01%. The company's revenue was up 2.7% on a year-over-year basis. During the same quarter last year, the company earned $0.91 earnings per share. View PerkinElmer's Earnings History.

When is PerkinElmer's next earnings date?

PerkinElmer is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for PerkinElmer.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer updated its FY19 earnings guidance on Monday, July, 29th. The company provided earnings per share (EPS) guidance of $4.02-4.07 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.05.

What price target have analysts set for PKI?

15 Wall Street analysts have issued 12-month price objectives for PerkinElmer's stock. Their predictions range from $41.00 to $115.00. On average, they anticipate PerkinElmer's stock price to reach $77.7083 in the next year. This suggests that the stock has a possible downside of 5.3%. View Analyst Price Targets for PerkinElmer.

What is the consensus analysts' recommendation for PerkinElmer?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 10 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PerkinElmer.

Has PerkinElmer been receiving favorable news coverage?

Press coverage about PKI stock has trended positive this week, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. PerkinElmer earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the next several days. View News Stories for PerkinElmer.

Who are some of PerkinElmer's key competitors?

What other stocks do shareholders of PerkinElmer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include Celgene (CELG), Honeywell International (HON), Thermo Fisher Scientific (TMO), Visa (V), Cisco Systems (CSCO), Illumina (ILMN), NVIDIA (NVDA), CVS Health (CVS), General Electric (GE) and Square (SQ).

Who are PerkinElmer's key executives?

PerkinElmer's management team includes the folowing people:
  • Mr. Robert F. Friel, Chairman & CEO (Age 63)
  • Dr. Prahlad R. Singh, Pres & COO (Age 54)
  • Mr. James M. Mock, Sr. VP & CFO (Age 42)
  • Mr. Joel S. Goldberg, Sr. VP of Admin., Gen. Counsel & Sec. (Age 50)
  • Mr. James Corbett, Exec. VP and Pres of Discovery & Analytical Solutions (Age 56)

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (16.27%), Vanguard Group Inc. (11.02%), BlackRock Inc. (6.66%), Janus Henderson Group PLC (5.65%), Janus Henderson Group PLC (5.65%) and Primecap Management Co. CA (2.44%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Frank Anders Wilson, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett, Prahlad R Singh and Robert F Friel. View Institutional Ownership Trends for PerkinElmer.

Which institutional investors are selling PerkinElmer stock?

PKI stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Invesco Ltd., Primecap Management Co. CA, Bank of America Corp DE, Schroder Investment Management Group, Westwood Holdings Group Inc., Amundi Pioneer Asset Management Inc. and Janus Henderson Group PLC. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett and Prahlad R Singh. View Insider Buying and Selling for PerkinElmer.

Which institutional investors are buying PerkinElmer stock?

PKI stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, BlackRock Inc., Sumitomo Mitsui Trust Holdings Inc., Echo Street Capital Management LLC, Pictet Asset Management Ltd., Allianz Asset Management GmbH, Swiss National Bank and UBS Asset Management Americas Inc.. View Insider Buying and Selling for PerkinElmer.

How do I buy shares of PerkinElmer?

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $82.04.

How big of a company is PerkinElmer?

PerkinElmer has a market capitalization of $9.11 billion and generates $2.78 billion in revenue each year. The medical research company earns $237.93 million in net income (profit) each year or $3.61 on an earnings per share basis. PerkinElmer employs 12,500 workers across the globe.View Additional Information About PerkinElmer.

What is PerkinElmer's official website?

The official website for PerkinElmer is http://www.perkinelmer.com/.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected]


MarketBeat Community Rating for PerkinElmer (NYSE PKI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  425 (Vote Outperform)
Underperform Votes:  445 (Vote Underperform)
Total Votes:  870
MarketBeat's community ratings are surveys of what our community members think about PerkinElmer and other stocks. Vote "Outperform" if you believe PKI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PKI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel